Oncternal Competitors

Delisted . USA . 
Stock . Oncternal Therapeutics
ONCTDelisted Stock  USD 0.53  0.00  0.00%   
Oncternal Therapeutics competes with CytomX Therapeutics, Assembly Biosciences, Instil Bio, Nuvation Bio, and Protara Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Oncternal Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Oncternal Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Oncternal Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Oncternal Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.030.5511.33
Details
Intrinsic
Valuation
LowRealHigh
0.030.5011.28
Details
Naive
Forecast
LowNextHigh
00.2311.01
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.300.791.28
Details

Oncternal Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Oncternal Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Oncternal and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Oncternal Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
VCNX
+ 0.73
NUVB
MIRO
+ 0.72
MNPR
MNPR
+ 0.65
TARA
MIRO
+ 0.61
NUVB
MIRO
+ 0.61
TARA
TIL
+ 0.58
NLTX
  
High negative correlations   
MNPR
- 0.75
TIL
MNPR
- 0.57
NLTX
TARA
- 0.55
NLTX
MIRO
- 0.51
TIL
TARA
- 0.48
TIL
MIRO
- 0.44
NLTX

Risk-Adjusted Indicators

There is a big difference between Oncternal Stock performing well and Oncternal Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oncternal Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Oncternal Therapeutics Competitive Analysis

The better you understand Oncternal Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Oncternal Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Oncternal Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ONCT NLTX CTMX ASMB TIL NUVB TARA VCNX MNPR MIRO
 0.00 
 0.53 
Oncternal
 1.43 
 0.69 
Neoleukin
 0.89 
 1.11 
CytomX
 0.20 
 15.38 
Assembly
 2.52 
 21.97 
Instil
 0.76 
 2.61 
Nuvation
 4.32 
 5.98 
Protara
 7.98 
 3.69 
Vaccinex
 4.66 
 25.38 
Monopar
 12.87 
 1.49 
Miromatrix
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Dangerous
Unstable
Relatively risky
Risky
Relatively risky
Very risky
Out of control
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Solid
Very Weak
OK
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Quite High
Low
Above Average
Average
Low
Average
Low
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Cautious Hold
Sell
Cautious Hold
Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Current Ratio
10.78
12.78
2.05
8.31
8.51
33.58
28.94
8.22
7.61
9.09
Net Asset
36.73 M
115.95 M
201.79 M
136.82 M
325.63 M
621.48 M
78.95 M
3.63 M
7.35 M
34.76 M
Profit Margin
N/A
N/A
0.11
-2.12
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
2.23 M
(56.48 M)
(4.31 M)
(64.2 M)
(146.12 M)
(99.6 M)
(43.27 M)
(19.75 M)
429.04 K
(29.91 M)
Operating Margin
-17.57
N/A
0.12
-1.43
N/A
-66.16
N/A
-24.66
N/A
-593.69
Current Valuation
(12.83 M)
(35.02 M)
(20.12 M)
4.25 M
108.37 M
340.5 M
46.6 M
8.55 M
126.68 M
80.11 M
Price To Book
0.17
0.44
5.04
3.76
0.81
1.75
1.51
7.34
27.08
5.98
Retained Earnings
(197.78 M)
(451.06 M)
(723.45 M)
(785.75 M)
(580.98 M)
(342.8 M)
(200.38 M)
(339.93 M)
(60.21 M)
(104.01 M)
Current Asset
27.27 M
289 K
189.75 M
68.37 M
N/A
N/A
N/A
N/A
11.55 M
N/A
Beta
1.33
1.1
1.06
0.59
1.74
1.36
1.79
0.99
1.1
0.015
Number Of Employees
27
7
120
65
49
203
26
37
9
76
Shares Outstanding
2.96 M
2.35 M
78.26 M
6.36 M
6.53 M
335.57 M
20.63 M
2.68 M
5.28 M
27.42 M
Cash Flow From Operations
(32.16 M)
(45.61 M)
(56.03 M)
22.74 M
(82.03 M)
(68 M)
(37.56 M)
(17.23 M)
(7.86 M)
(26.68 M)
Total Debt
318 K
12.07 M
13.97 M
2.34 M
86.05 M
4.01 M
5.47 M
247 K
1.76 M
3.55 M
Return On Equity
-1.5
-0.38
-54.75
-1.02
-0.49
-0.96
-0.46
-7.59
-1.02
-1.14
Z Score
N/A
-5.73
N/A
N/A
N/A
N/A
N/A
N/A
N/A
9.47
Return On Asset
-0.76
-0.19
0.0233
-0.35
-0.12
-0.14
-0.28
-4.96
-0.53
-0.56
Number Of Shares Shorted
14.21 K
26.4 K
4.39 M
15.88 K
243.79 K
14.07 M
3.02 M
62.11 K
21.98 K
11.66 K
Book Value Per Share
3.09
34.18
-0.3
7.5
34.72
1.5
6.01
-2.59
1.88
0.57
Current Liabilities
6.3 M
1.02 M
15.74 M
3.4 M
N/A
N/A
N/A
N/A
598.26 K
N/A
Total Asset
36.73 M
115.95 M
201.79 M
136.82 M
325.63 M
621.48 M
78.95 M
3.63 M
7.35 M
34.76 M
Debt To Equity
0.002
0.11
0.67
0.041
0.12
0.006
0.046
0.024
0.002
0.095
Short Ratio
0.09
1.7
4.32
0.41
2.29
5.52
14.46
0.74
0.15
0.03
Target Price
2.0
1.5
5.29
35.5
100.33
6.5
26.4
7.0
27.33
3.13
Shares Owned By Institutions
12.07
45.58
65.62
18.79
80.7
56.12
51.1
49.12
24.47
25.75
Market Capitalization
1.56 M
8.2 M
86.87 M
97.76 M
143.37 M
878.44 M
123.37 M
9.88 M
133.95 M
92.95 M
Price To Earning
-37.77
-4.6
-11.41
-10.58
18.31
N/A
N/A
N/A
-35.82
N/A
Price To Earnings To Growth
N/A
-0.03
-1.8
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.72
N/A
0.69
4.55
55329.79
406.31
N/A
27.74
N/A
97.02
Net Income
(39.48 M)
(57.56 M)
(569 K)
(61.23 M)
(156.09 M)
(75.8 M)
(40.42 M)
(20.25 M)
(8.4 M)
(29.96 M)
Earnings Per Share
-11.69
-12.28
0.16
-6.89
-11.56
-2.18
-2.64
7.42
-1.98
-1.14
Shares Owned By Insiders
9.23
16.46
1.0
31.62
12.86
26.85
6.12
9.36
42.94
23.95
Revenue
785 K
N/A
101.21 M
7.16 M
N/A
N/A
N/A
570 K
N/A
953.47 K
Working Capital
30.86 M
88.07 M
27.02 M
94.56 M
150.2 M
602.46 M
62.56 M
(2.57 M)
5.58 M
22.36 M
Cash And Equivalents
78.9 M
116.46 M
194.29 M
116.69 M
354.61 M
703.8 M
98.46 M
11.4 M
16.46 M
32.67 M
Cash Per Share
1.48
2.73
2.94
2.41
2.73
3.22
8.74
0.27
1.29
1.56
Gross Profit
(31.49 M)
N/A
53.16 M
(63.9 M)
138 K
N/A
N/A
(13.7 M)
N/A
(466.93 K)
Day Typical Price
0.53
0.69
1.1
15.25
21.62
2.6
6.0
3.82
25.02
1.56
Accumulation Distribution
N/A
0.0563
0.0708
0.0273
0.0784
0.0341
0.12
0.1
0.0666
0.14
Market Facilitation Index
N/A
0.04
0.08
0.42
1.75
0.09
0.76
0.43
1.71
0.24
Daily Balance Of Power
0.0
(0.25)
(0.12)
0.0714
0.3086
(0.22)
(0.36)
(0.74)
0.6608
(0.92)
Period Momentum Indicator
N/A
(0.01)
(0.01)
0.03
0.54
(0.02)
(0.27)
(0.32)
1.13
(0.22)
Rate Of Daily Change
1.0
0.99
0.99
1.0
1.03
0.99
0.96
0.92
1.05
0.87
Day Median Price
0.53
0.69
1.09
15.19
21.45
2.6
6.01
3.89
24.84
1.59
Price Action Indicator
N/A
(0.01)
0.015
0.21
0.79
0.005
(0.16)
(0.35)
1.11
(0.21)
Relative Strength Index
34.03
62.53
48.79
32.59
40.56
63.71
63.26
55.53
61.8
61.11
Coefficient Of Variation
(588.70)
(2,179)
(3,825)
(2,768)
(2,602)
(3,283)
448.47
(5,016)
785.08
1551.16
Mean Deviation
7.09
2.25
2.94
2.86
7.31
3.4
5.58
6.55
19.0
4.85
Jensen Alpha
(2.04)
(0.18)
(0.23)
(0.20)
(0.79)
(0.48)
2.39
(0.24)
10.01
0.5061
Total Risk Alpha
(3.66)
(0.64)
(0.61)
(0.69)
(2.09)
(0.72)
1.01
(1.34)
0.2228
(0.42)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
0.4899
N/A
0.7883
0.0563
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
20.35
N/A
144.06
36.83
Standard Deviation
12.41
3.7
3.96
4.22
12.79
4.56
10.36
9.2
75.06
6.85
Kurtosis
9.61
13.95
1.44
3.54
26.45
0.8028
28.42
2.32
63.85
2.54
Potential Upside
11.49
4.05
6.78
8.79
13.62
9.48
13.0
11.52
15.92
11.73
Treynor Ratio
2.39
(6.84)
(0.09)
(0.38)
(0.16)
(0.04)
(2.21)
(0.35)
(1.87)
(0.52)
Maximum Drawdown
82.86
27.84
22.92
21.34
105.83
21.3
76.35
54.95
653.56
38.49
Variance
154.07
13.69
15.66
17.81
163.5
20.79
107.35
84.72
5634.66
46.97
Market Risk Adjusted Performance
2.4
(6.83)
(0.08)
(0.37)
(0.15)
(0.03)
(2.20)
(0.34)
(1.86)
(0.51)
Risk Adjusted Performance
(0.11)
(0.03)
(0.01)
(0.02)
(0.02)
(0.01)
0.171
(0.01)
0.1023
0.0557
Skewness
(1.07)
(2.77)
0.5164
(0.27)
4.18
0.3297
4.53
(0.87)
7.92
0.9188
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
3.43
N/A
8.18
5.26
Information Ratio
(0.18)
(0.07)
(0.05)
(0.06)
(0.05)
(0.05)
0.2133
(0.03)
0.126
0.0499
Value At Risk
(20.35)
(3.53)
(5.22)
(6.46)
(10.89)
(8.36)
(6.13)
(16.55)
(11.81)
(8.87)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
(8.21)
N/A
(22.58)
(6.37)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
4.51
N/A
12.0
6.07
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
11.75
N/A
66.91
27.65

Oncternal Therapeutics Competition Performance Charts

Five steps to successful analysis of Oncternal Therapeutics Competition

Oncternal Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Oncternal Therapeutics in relation to its competition. Oncternal Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Oncternal Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Oncternal Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Oncternal Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Oncternal Therapeutics position

In addition to having Oncternal Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Investment Grade ETFs Thematic Idea Now

Investment Grade ETFs
Investment Grade ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 263 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Oncternal Stock

If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY